Because AAT therapy has shown beneficial effects in inflammation-related disease models for rheumatoid arthritis, lupus, and type 1 diabetes (T1D) [27,28], we overexpressed human AAT (hAAT) in MSCs to show improved intrinsic properties and sustained efficacy in mice with T1D [28]. This evidence concerns the gene SERPINA1 and type 1 diabetes mellitus.